Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GW 766994 is a specific and oral chemokine receptor-3 (CCR3) antagonist. It has the potential for asthma and eosinophilic bronchitis treatment.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 275,500 |
50 mg | 約6-8 週間 | ¥ 358,000 |
100 mg | 約6-8 週間 | ¥ 574,000 |
ターゲット&IC50 | CCR3:7.86 (pki) |
In vitro | GW 766994 (10 μM) counteracts CCL11-induced CDK5 activation, CDK5 and GSK3β phosphorylations, and the heightened phosphorylation of tau in hippocampal neurons. As a specific chemokine receptor-3 (CCR3) antagonist, GW 766994 has progressed to clinical trials for the treatment of asthma and eosinophilic bronchitis. |
別名 | GW 994 |
分子量 | 451.35 |
分子式 | C21H24Cl2N4O3 |
CAS No. | 408303-43-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 56 mg/mL (124.07 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GW 766994 408303-43-5 Immunology/Inflammation Microbiology/Virology CCR GW994 GW-766994 GW766994 GW 994 GW-994 Inhibitor inhibitor inhibit